Jafron Biomedical Co

Jafron Biomedical Co Equity Growth

The Year-over-Year Equity Growth of Jafron Biomedical Co (300529.SZ) as of Nov 13, 2026 is 4.13 %. In the previous year, Year-over-Year Equity Growth was 5.92 % — a change of -30.21% (lower).

Equity Growth

4.13 %

YoY

-30.21%

Last updated:

Year-over-Year Equity Growth of Jafron Biomedical Co is 2025 4.13 % . Year-over-Year Equity Growth of Jafron Biomedical Co was 2024 5.92 % . It decreases by -30.21% lower compared to the previous year.

The Jafron Biomedical Co Equity Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Growth
Date
Equity Growth
Jan 1, 2018
22.10 CNY
Jan 1, 2019
26.14 CNY
Jan 1, 2020
31.01 CNY
Jan 1, 2021
19.67 CNY
Jan 1, 2022
6.41 CNY
Jan 1, 2023
-11.94 CNY
Jan 1, 2024
5.92 CNY
Jan 1, 2025
4.13 CNY
The Jafron Biomedical Co Equity Growth history
YEAREquity GrowthYoY
4.13 %-30.21%
5.92 %-149.60%
-11.94 %-286.18%
6.41 %-67.39%
19.67 %-36.57%
31.01 %+18.62%
26.14 %+18.30%
22.10 %+26.38%
17.49 %-84.09%
109.92 %+345.43%
24.68 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Jafron Biomedical Co Stock analysis

What does Jafron Biomedical Co do? Jafron Biomedical Co., Ltd. generates revenue through the research, development, production, and sale of hemoperfusion products and medical equipment. The company offers a range of items including disposable hemoperfusion devices, hemoperfusion machines, disposable bilirubin adsorbers, the DX-10 blood purification machine, suture needles, and resins bandage. These products are utilized for treating conditions such as uremia, poisoning, severe liver diseases, autoimmune diseases, and multisystem organ failure. The primary customers for these medical solutions are hospitals across China, where the company’s products are applied in more than 3000 hospitals within 31 provinces. As a China-based company, Jafron Biomedical Co., Ltd. focuses on the design, manufacture, and distribution of biological materials and medical equipment to support healthcare providers in these regions. The company operates from its headquarters in Zhuhai, Guangdong, and supports its operations with a workforce of 3,003 full-time employees. By engaging in the full lifecycle of its products from research to sale, the firm serves the medical sector with specialized equipment for blood purification and related therapeutic needs. Jafron Biomedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Jafron Biomedical Co stock

Year-over-Year Equity Growth of Jafron Biomedical Co is 4.13 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Equity Growth Jafron Biomedical Co since 2006 – with annual values, charts, and detailed analysis.

Equity growth measures the percentage change in shareholders' equity. It reflects retained earnings, share issuances, and comprehensive income effects.

To evaluate Year-over-Year Equity Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Equity Growth.

Year-over-Year Equity Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Equity Growth's Jafron Biomedical Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Jafron Biomedical Co

All Key Metrics — Jafron Biomedical Co